MA30044B1 - Procede de traitement - Google Patents

Procede de traitement

Info

Publication number
MA30044B1
MA30044B1 MA31021A MA31021A MA30044B1 MA 30044 B1 MA30044 B1 MA 30044B1 MA 31021 A MA31021 A MA 31021A MA 31021 A MA31021 A MA 31021A MA 30044 B1 MA30044 B1 MA 30044B1
Authority
MA
Morocco
Prior art keywords
ocular neovascular
administration
treating
methods
derivatives
Prior art date
Application number
MA31021A
Other languages
English (en)
Inventor
Mark Levick
William Henry Miller
Richard Anthony Brigandi
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA30044B1 publication Critical patent/MA30044B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

La présente invention concerne des procédés de traitement d'un trouble néovasculaire oculaire chez un mammifère par l'administration de dérivés de pyrimidine, de dérivés de benzodiazépinyle et des compositions pharmaceutiques en contenant. L'invention concerne également des procédés de traitement d'un trouble néovasculaire oculaire par l'administration de l'acide 5-[[4-[(2,3-diméthyl-2H-indazol-6-yl)méthylamino]-2-pyrimidinyl]amino]-2-méthylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroéthyl)-2,3,4,5-tétrahydro-1H-2-benzazépine-4-acétique ou des sels et des solvates de celui-ci. L'invention concerne en outre des thérapies de combinaison pour le traitement de troubles néovasculaires oculaires.
MA31021A 2005-11-29 2008-06-11 Procede de traitement MA30044B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74047805P 2005-11-29 2005-11-29

Publications (1)

Publication Number Publication Date
MA30044B1 true MA30044B1 (fr) 2008-12-01

Family

ID=38037895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31021A MA30044B1 (fr) 2005-11-29 2008-06-11 Procede de traitement

Country Status (28)

Country Link
US (1) US20080293691A1 (fr)
EP (2) EP2329821B1 (fr)
JP (1) JP5180834B2 (fr)
KR (1) KR20080071188A (fr)
CN (1) CN101370505B (fr)
AT (1) ATE482708T1 (fr)
AU (2) AU2006320535B2 (fr)
BR (1) BRPI0619057A2 (fr)
CA (1) CA2631173A1 (fr)
CR (1) CR10010A (fr)
CY (1) CY1111047T1 (fr)
DE (1) DE602006017261D1 (fr)
DK (1) DK1968594T3 (fr)
EA (1) EA016227B1 (fr)
ES (2) ES2350858T3 (fr)
HK (1) HK1121386A1 (fr)
HR (1) HRP20100559T1 (fr)
IL (1) IL191027A0 (fr)
MA (1) MA30044B1 (fr)
MX (1) MX2008006379A (fr)
MY (1) MY144750A (fr)
NO (1) NO20081963L (fr)
NZ (1) NZ568075A (fr)
PL (1) PL1968594T3 (fr)
PT (1) PT1968594E (fr)
SI (1) SI1968594T1 (fr)
UA (1) UA94427C2 (fr)
WO (1) WO2007064752A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069576A1 (fr) 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Compositions therapeutiques utilisees pour le traitement des affections inflammatoires oculaires
US8076475B2 (en) 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
CN102573477A (zh) * 2009-07-16 2012-07-11 葛兰素惠尔康制造业私人有限公司 治疗方法
US20120197019A1 (en) * 2009-10-23 2012-08-02 Dharmesh Surendra Bhanushali Compositions and processes
WO2011058179A1 (fr) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5-(4-(n-(2,3-diméthyl-2h-indazol-6-yl)-n-méthylamino)pyrimidin-2-ylamino)-2-méthylbenzènesulfonamide
WO2011069053A1 (fr) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Procede de preparation de pazopanip hcl et formes cristallines de pazopanib hcl
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
WO2013022801A1 (fr) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
CA2818215C (fr) * 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions et methodes de traitement d'un oedeme oculaire, de neovascularisation et de maladies associees
CA2818612C (fr) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Formulations d'agents therapeutiques pour des dispositifs implantes
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
EA201400064A1 (ru) 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
PL2755600T3 (pl) 2011-09-16 2021-09-20 Forsight Vision4, Inc. Urządzenie do wymiany płynów
KR101993436B1 (ko) 2011-10-31 2019-06-26 노바르티스 아게 파조파닙 제형
JP2015500221A (ja) 2011-12-01 2015-01-05 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 眼疾患の治療および予防方法
CN102657655B (zh) * 2012-05-17 2014-05-21 大连理工大学 嘧啶胺类化合物在制备乙酰胆碱酯酶抑制剂中的应用
US20150174096A1 (en) 2012-06-12 2015-06-25 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
US9802923B2 (en) 2012-12-17 2017-10-31 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
WO2014097152A1 (fr) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Procédé de préparation du pazopanib ou de ses sels
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2015068175A2 (fr) 2013-11-05 2015-05-14 Laurus Labs Private Limited Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN107072203B (zh) 2014-09-09 2020-07-03 赫雷拉 A·索利斯 用黑色素及其类似物、前体和衍生物治疗和预防眼部疾病、障碍和病症的方法
CN110478119B (zh) 2014-11-10 2022-04-15 弗赛特影像4股份有限公司 可膨胀药物递送装置和使用方法
CA3010056A1 (fr) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Anticorps et conjugues de ceux-ci
AU2017205185B2 (en) 2016-01-07 2022-03-31 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
JP2020536967A (ja) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送***的流体交换装置及使用方法
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法
EP4041312A4 (fr) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
DE3905050A1 (de) 1989-02-18 1990-08-30 Lohmann Therapie Syst Lts Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii)
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (fr) 1992-05-05 1995-07-07 Aiache Jean Marc Forme galenique pour administration oculaire et procede de preparation.
WO1995003009A1 (fr) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Methode de traitement de la degenerescence maculaire
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5710165A (en) 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
JP3251294B2 (ja) 1994-11-10 2002-01-28 ユニヴァーシティ オブ ケンタッキー リサーチ ファウンデーション 体内に薬剤を直接送出する、移植・補充可能な放出制御装置
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5743274A (en) 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US5824073A (en) 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
ES2232005T3 (es) 1997-08-11 2005-05-16 Allergan, Inc. Dispositivo de implante biodegradable esteril que contiene retinoide con biocompatibilidad mejorada y metodo de preparacion.
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6146366A (en) 1998-11-03 2000-11-14 Ras Holding Corp Device for the treatment of macular degeneration and other eye disorders
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6660960B2 (en) 1999-12-28 2003-12-09 K. K. Endo Seisakusho Method for manufacturing golf club
PT1313415E (pt) 2000-08-30 2008-11-25 Univ Johns Hopkins Dispositivos para entrega intra-ocular de fármacos
ES2324981T3 (es) * 2000-12-21 2009-08-21 Smithkline Beecham Corporation Pirimidinaminas como moduladores de la angiogenesis.
US7592016B2 (en) 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
AU2002324811B2 (en) 2001-08-29 2008-07-24 De Carvalho, Ricardo A P An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
US7749528B2 (en) 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
WO2003092669A2 (fr) * 2002-05-03 2003-11-13 Alcon, Inc. Procede de traitement des troubles vasculaires medies par le facteur de croissance endothelial
AU2003276125B2 (en) * 2002-06-17 2007-05-17 Smithkline Beecham Corporation Chemical process
WO2005105094A2 (fr) * 2004-04-16 2005-11-10 Smithkline Beecham Corporation Methode de traitement du cancer
EP2319492A3 (fr) * 2004-10-21 2011-08-10 Genentech, Inc. Procédé pour le traitement de maladies néovasculaires intraoculaires
WO2006117666A2 (fr) * 2005-04-29 2006-11-09 Pfizer Inc. Formes posologques, compositions pharmaceutiques et methodes d'administration sous la capsule de tenon

Also Published As

Publication number Publication date
CA2631173A1 (fr) 2007-06-07
EP1968594B1 (fr) 2010-09-29
AU2006320535A1 (en) 2007-06-07
EA016227B1 (ru) 2012-03-30
KR20080071188A (ko) 2008-08-01
JP5180834B2 (ja) 2013-04-10
WO2007064752A2 (fr) 2007-06-07
NZ568075A (en) 2010-12-24
DK1968594T3 (da) 2010-12-13
BRPI0619057A2 (pt) 2011-09-20
JP2009517396A (ja) 2009-04-30
MY144750A (en) 2011-10-31
AU2006320535B2 (en) 2010-09-23
IL191027A0 (en) 2009-08-03
EP2329821A1 (fr) 2011-06-08
MX2008006379A (es) 2009-03-03
WO2007064752A3 (fr) 2008-08-14
CN101370505B (zh) 2012-03-21
EP2329821B1 (fr) 2012-08-22
DE602006017261D1 (de) 2010-11-11
PL1968594T3 (pl) 2011-03-31
ATE482708T1 (de) 2010-10-15
CY1111047T1 (el) 2015-06-11
SI1968594T1 (sl) 2011-01-31
HK1121386A1 (en) 2009-04-24
UA94427C2 (ru) 2011-05-10
AU2010249187A1 (en) 2011-01-06
HRP20100559T1 (hr) 2010-11-30
ES2350858T3 (es) 2011-01-27
CN101370505A (zh) 2009-02-18
CR10010A (es) 2008-11-03
EA200801168A1 (ru) 2008-10-30
ES2392030T3 (es) 2012-12-04
PT1968594E (pt) 2010-11-18
NO20081963L (no) 2008-08-26
US20080293691A1 (en) 2008-11-27
EP1968594A2 (fr) 2008-09-17

Similar Documents

Publication Publication Date Title
MA30044B1 (fr) Procede de traitement
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
ATE500831T1 (de) Krebsbehandlungsverfahren
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
MA29795B1 (fr) Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete
NO20040511L (no) Aminoisoxazolderivater som kinaseinhibitorer
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
WO2006130522A3 (fr) Methodes et compositions pour traiter des troubles psychotiques
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
PT1240165E (pt) Inibidores n-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]carboxamida de quinases dependentes da ciclina
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
NO20052059D0 (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
TW200730507A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0507802A (pt) composto, composição, e, método para tratar inflamação ou um distúrbio metabólico
DE60327634D1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
BR0212175A (pt) Sal de bissulfato de uma 3-fenil-3-dimetilaminoalquil-4,4-dimetilpiperidin-2,6-di ona, composição farmacêutica, uso de um sal de bissulfato de uma 3-fenil-3-dimetilamino-alquil-4,4-dimetilpiperidin-2,6-d iona, e, método para o tratamento ou a profilaxia de um distúrbio afetivo relacionado com a tensão
MY128882A (en) Novel use of substituted aminomethyl chromans
BR0307427A (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica, método para tratar de um paciente humano ou animal que esteja sofrendo de uma condição que seja medida por cox-2, e, uso de uma composição farmacêutica